1. Executive Summary
1.1 Biosimilars and Follow-On Biologics: Word Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Terminology Used in this Report
1.5 Scope of the Report
2. Introduction to Biosimilars and Follow-On Biologics
2.1 Biological Drugs
2.1.1 A History of Biologics
2.2 Classes of Biologic
2.2.1 Monoclonal Antibodies
2.2.2 Fusion Proteins
2.2.3 Insulin
2.2.4 Interferons
2.2.5 Growth Hormones
2.2.6 Erythropoietin
2.2.7 Granulocyte Colony-Stimulating Factor
2.2.8 Other Biologic Drugs
2.3 Biosimilars
2.3.1 Biosimilar Development
2.3.2 Interest in Biosimilar Development
2.3.3 Demand for Biosimilars
3. The Biosimilars Market 2012-2022
3.1 The Biologics Market 2011
3.2 The Biologics Market: Overall Revenue Forecast 2012-2022
3.3 The Biosimilars Market 2011
3.4 The Biosimilars Market: Overall Revenue Forecast 2012-2022
3.4.1 Demand for Monoclonal Antibodies and Insulin
3.4.2 Continued Growth of Biosimilar Erythropoietins, G-CSF and Growth Hormones
4. Leading National Biosimilar Markets 2012-2022
4.1 Leading National Markets 2011
4.2. Leading National Markets: Revenue Forecasts 2012-2022
4.3 The US
4.3.1 US: Biosimilar Revenues 2011
4.3.2 US: Biosimilar Revenues 2012-2022
4.4 The EU
4.4.1 The EU: Biosimilar Revenues 2011
4.4.2 The EU: Biosimilar Revenues 2012-2022
4.4.3 Germany: Biosimilar Revenues 2012-2022
4.4.4 France: Biosimilar Revenues 2012-2022
4.4.5 The UK: Biosimilar Revenues 2012-2022
4.4.6 Spain: Biosimilar Revenues 2012-2022
4.4.7 Italy: Biosimilar Revenues 2012-2022
4.5 Japan
4.5.1 Japan: Biosimilar Revenues 2011
4.5.2 Japan: Biosimilar Revenues 2012-2022
4.5.3 New Approval Submissions 2011-2012
4.5.4 Key Players in the Future Japanese Biosimilars Market
4.5.4.1 Nippon Kayaku
4.5.4.2 Nichi-Iko Pharmaceutical
4.6 China
4.6.1 China: Biosimilar Revenues 2011
4.6.1.1 A Fragmented Market
4.6.2 China: Biosimilar Revenues 2012-2022
4.7 India
4.7.1 India: Biosimilar Revenues 2011
4.7.2 India: Biosimilar Revenues 2012-2022
4.8 South Korea
4.8.1 South Korea: Biosimilar Revenues 2011
4.8.2 South Korea: Biosimilar Revenues 2012-2022
4.8.2.1 Keen to Become a Leading Market Player
5. Biosimilar Monoclonal Antibodies and Fusion Proteins Submarket 2012-2022
5.1 The Monoclonal Antibodies and Fusion Proteins Submarket 2011
5.2 The Monoclonal Antibodies and Fusion Proteins Submarket: Revenue Forecast 2012-2022
5.2.1 Monoclonal Antibodies and Cancer
5.3 The Biosimilar Monoclonal Antibodies and Fusion Proteins Submarket 2011
5.3.1 Reditux (Rituximab, Dr Reddy's Laboratories)
5.4 The Biosimilar Monoclonal Antibodies and Fusion Proteins Submarket: Revenue Forecast 2012-2022
5.5 Biosimilar Monoclonal Antibodies Pipeline 2012
5.5.1 EMA Development Guidelines
5.5.1.1 Non-Clinical Studies
5.5.1.2 Clinical Studies and Clinical Safety
5.5.1.3 Expanding Indications
5.5.2 Biosimilar Competition for Rituxan
5.5.3 Biosimilar Competition for Herceptin
5.5.4 Biosimilar Competition for Enbrel
5.5.5 Biosimilar Competition for Remicade
6. Biosimilar Insulin Submarket 2012-2022
6.1 Insulin Submarket 2011
6.2 Insulin Submarket: Revenue Forecast 2012-2022
6.2.1 Rising Incidence of Diabetes
6.3 Biosimilar Insulin Submarket 2011
6.3.1 Gensulin/SciLin (Bioton/SciGen)
6.3.2 Wosulin/Glaritus (Wockhardt)
6.3.3 Insugen (Biocon)
6.4 Biosimilar Insulin in the EU and US
6.4.1 Approval Application Withdrawals in the EU
6.4.2 EMA to Update Developmental Guidelines
6.4.3 Actavis to Commercialise Bioton's Insulin
6.5 Biosimilar Insulin Submarket: Revenue Forecast 2012-2022
7. Biosimilar Interferons Submarket 2012-2022
7.1 Interferon Submarket 2011
7.1.1 Declining Interferon Alpha Revenues
7.2 Interferon Submarket: Revenue Forecast 2012-2022
7.2.1 Rise of Oral Agents for MS and Hepatitis C
7.3 Biosimilar Interferon Submarket 2011
7.3.1 Interferon Alpha Biosimilars
7.3.2 CinnoVex (Interferon Beta-1a, CinnaGen)
7.3.3 Biosimilar Interferon Failures
7.4 Biosimilar Interferon Submarket: Revenue Forecast 2012-2022
7.5 Biosimilar Interferon Pipeline 2012
7.5.1 Pegylated Interferon Alpha
7.5.2 Challenges in Developing Biosimilar Interferons
7.5.3 European Biosimilar Interferon Beta Guidelines
7.5.3.1 Comparison with Biosimilar Interferon Alpha Guidelines
8. Other Leading Biosimilar Submarkets 2012-2022
8.1 Biosimilar Erythropoietins Submarket 2012-2022
8.1.1 Erythropoietins Submarket 2011
8.1.1.1 Safety Concerns and Label Updates
8.1.1.2 Declining Revenues
8.1.2 Erythropoietins Submarket: Revenue Forecast 2012-2022
8.1.3 Biosimilar Erythropoietins Submarket 2011
8.1.3.1 Sandoz' Biosimilar Erythropoietin
8.1.3.2 Hospira's Biosimilar Erythropoietin
8.1.3.3 Biosimilar Erythropoietins in Emerging Markets
8.1.4 Biosimilar Erythropoietins Submarket: Revenue Forecast 2012-2022
8.1.4.1 Biosimilar Darbepoetin Alpha
8.2 Biosimilar G-CSF Submarket 2012-2022
8.2.1 G-CSF Submarket 2011
8.2.2 G-CSF Submarket: Revenue Forecast 2012-2022
8.2.3 Biosimilar G-CSF Submarket 2011
8.2.3.1 Biosimilar G-CSF Available in Europe
8.2.3.2 Biosimilar G-CSF Available in Emerging Markets
8.2.4 Biosimilar G-CSF Submarket: Revenue Forecast 2012-2022
8.2.4.1 Biosimilar Pegfilgrastim
8.2.4.2 Biosimilar G-CSF in the US
8.3 Biosimilar Growth Hormones Submarket 2012-2022
8.3.1 Growth Hormones Submarket 2011
8.3.1.1 Dominance of Two Brands
8.3.2 Growth Hormones Submarket: Revenue Forecast 2012-2022
8.3.2.1 Overcoming Safety Concerns
8.3.3 Biosimilar Growth Hormones Submarket 2011
8.3.3.1 Omnitrope: A World Leading Biosimilar
8.3.3.2 Eutropin/Valtropin
8.3.4 Biosimilar Growth Hormone Submarket: Revenue Forecast 2012-2022
9. Regulatory Outlook for Biosimilars 2012-2022
9.1 US Biosimilar Regulation and Approval
9.1.1 The Patient Protection and Affordable Care Act 2010
9.1.2 Biologic Data and Market Exclusivity
9.1.3 Naming Biosimilars
9.1.4 Biosimilar Interchangeability
9.1.5 FDA Draft Guidelines 2012
9.1.5.1 Pre-Clinical Requirements
9.1.5.2 Clinical Trial Requirements
9.1.6 Biosimilar Approval Timeline
9.2 Biosimilar Regulation and Approval in the EU
9.2.1 Pre-Clinical Testing Demands
9.2.2 Guidelines for Clinical Trials
9.2.3 Extrapolation for Additional Indications
9.2.4 Naming Biosimilars
9.2.5 Biosimilar Substitution
9.2.6 Data and Marketing Exclusivity
9.2.7 A Template for Other Countries
9.2.8 EMA Guideline Updates 2011-2012
9.2.8.1 Biosimilar Monoclonal Antibodies
9.2.8.2 Biosimilar Interferon Beta
9.2.8.3 Biosimilar Follicle Stimulating Hormone
9.2.8.4 Review of General Biosimilar Guidelines
9.3 Japanese Biosimilar Regulations
9.3.1 Biosimilar Approval and Development Guidelines
9.3.2 Naming Biosimilars
9.4 Biosimilar Regulation in Emerging Markets
9.5 China's Biosimilar Regulations
9.6 Biosimilar Approval in India
9.6.1 Biosimilar Regulatory Pathway Development
9.7 Biosimilar Regulation in South Korea
9.7.1 Biosimilar Guidelines
10. Biosimilars: Industry Trends 2012-2022
10.1 Strengths and Weaknesses in the Biosimilars Market 2011
10.2 Opportunities and Threats in the Biosimilars Market 2012-2022
10.2.1 Social Factors
10.2.2 Technological Developments
10.2.3 Economic Pressures
10.2.4 Political Issues
10.3 Biosimilar Market Entry
10.3.1 Cost as a Barrier to Entry
10.3.2 Interest from Big Pharma
10.3.3 Patents for Biologics
10.3.3.1 Targeting Monoclonal Antibodies
10.3.3.2 Innovators Protecting Intellectual Property
10.4 Biosimilar Development: Opportunities and Challenges
10.4.1 Data Exclusivity
10.4.2 Pre-Clinical Biosimilar Development
10.4.3 Molecular Complexity
10.4.4 Biosimilars and Clinical Trials
10.4.5 Monoclonal Antibodies and Surrogate Endpoints
10.4.6 Issues for Biologics and Biosimilars
10.4.6.1 Immunogenicity: A Pre- and Post-Marketing Consideration
10.4.6.2 Biosimilarity
10.4.7 An Opportunity for Contract Research Organisations (CROs)
10.5 Commercialisation of Biosimilars
10.5.1 An Opportunity for Contract Manufacturing Organisations (CMOs)
10.5.2 Biosimilar Substitution
10.5.3 Physician Response to Biosimilars
10.5.4 Payer Demands for Data
10.5.5 Pharmacovigilance
10.5.6 Naming Biosimilars
10.5.7 Biosimilar Uptake
10.5.8 Biosimilars Offer Cost Savings
10.5.8.1 Healthcare Payers Demand Lower Costs
10.5.9 Biobetters Are an Alternative Market Strategy
11. Leading Biosimilar Developers and Manufacturers 2012
11.1 Leading Suppliers of Biosimilars 2011
11.2 3SBio
11.2.1 Financial Performance 2010
11.2.2 Biosimilar Pipeline 2012
11.3 Biocon
11.3.1 Financial Performance 2011
11.3.2 Insulin for Developed Markets
11.3.3 Mylan: Monoclonal Antibody Collaboration
11.4 Bioton
11.4.1 Presence in Europe and Asia
11.4.2 Actavis Collaboration
11.5 Dr. Reddy's Laboratories
11.5.1 Biosimilar Portfolio 2012
11.5.2 Biosimilar Pipeline 2012
11.6 Hospira
11.6.1 Biosimilars in the US
11.7 Intas Biopharmaceuticals
11.7.1 Apotex
11.8 LG Life Sciences
11.8.1 Biosimilar Pipeline 2012
11.9 Reliance Life Sciences
11.9.1 Reliance GeneMedix
11.10 Sandoz
11.10.1 Biosimilar Pipeline 2012
11.10.2 Targeting the US
11.11 Stada
11.11.1 Stada and Gedeon Richter
11.12 Teva
11.12.1 Ratiopharm
11.12.2 Biosimilar Pipeline 2012
11.12.2.1 Biosimilar Rituxan
11.13 Wockhardt
11.13.1 Deals for Developed Markets
11.14 Zydus Cadila
11.15 Leading Developers of Biosimilars 2012-2022
11.16 Celltrion
11.16.1 Market Launch Strategy
11.16.1.1 Entering the US and EU
11.17 Merck & Co.
11.17.1 Merck Collaborates with Hanwha Chemical
11.17.2 Biosimilar Pipeline 2012
11.18 Momenta Pharmaceuticals
11.18.1 Momenta and Baxter International
11.19 Samsung
11.19.1 Samsung BioLogics and Biogen Idec
11.20 Watson Pharmaceuticals
11.20.1 Collaboration with Amgen
11.21 Strategy Analysis
11.21.1 Emerging Markets as a Springboard to Developed Markets
11.21.2 Partnering to Succeed
12. Research Interviews
12.1 Anjan Selz, CEO, Finox
12.1.1 Finox
12.1.2 Challenges in Biosimilar Development
12.1.3 Differences Between Europe and the US
12.1.4 Product Differentiation
12.1.5 Opportunities Existing in the Biosimilars Market
12.2 Dr Robin Thorpe, Head, Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC) [UK]
12.2.1 Immunogenicity in Biosimilars
12.2.2 Biosimilar Uptake in Europe
12.2.3 Biosimilar Monoclonal Antibodies
12.3 Cecil Nick, VP (Biotechnology), Parexel Consulting
12.3.1 Challenges in Biosimilar Development
12.3.2 Asian Biosimilar Development
12.3.3 Biosimilar Interferons
12.4 Dr Jason Kantor, Managing Director, RBC Capital Markets
12.4.1 Challenges in Developing Biosimilars
12.4.2 Biosimilar Pricing
12.4.3 Next-Generation Antibody Therapies
13. Conclusions
13.1 State of the Global Biosimilars Market 2011
13.2 Growth in the Biosimilars Market 2012-2022
13.2.1 Targeting Monoclonal Antibodies
13.3 The Rise of the US Biosimilars Market
13.4 Many Opportunities - and Challenges - Exist in the Market
List of Tables
Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Comparative Biological Molecule Sizes
Table 2.2 Monoclonal Antibodies Approved in the US, 2012
Table 2.3 Insulin Peak Action Times
Table 3.1 Biological Drugs: Market Shares by Sector, 2011
Table 3.2 Biological Drugs Market: Overall Market and Revenue Forecasts by Class, 2011-2022
Table 3.3 Biosimilars: Market Shares by Sector, 2011
Table 3.4 Biosimilars Market: Overall Market and Revenue Forecasts by Class, 2011-2022
Table 3.5 Biosimilars Submarket Shares, 2011, 2016 and 2022
Table 4.1 Biosimilars: Market Shares by Region, 2011
Table 4.2 Biosimilars Market: Revenue Forecasts by Region, 2011-2022
Table 4.3 Biosimilars: Submarket Shares by Region, 2011, 2016 and 2022
Table 4.4 Global Pharmaceutical and Generics Markets: US Share, 2011
Table 4.5 US Biosimilars: Submarket Forecast, 2011-2022
Table 4.6 European Biosimilars: Market Size by Country, 2011
Table 4.7 European Approved Biosimilars, 2012
Table 4.8 European Biosimilars Market: Revenue Forecasts by Leading Country, 2011-2022
Table 4.9 German Biosimilars: Submarket Forecast, 2011-2022
Table 4.10 French Biosimilars: Market Shares by Sector, 2011
Table 4.11 French Biosimilars: Submarket Forecast, 2011-2022
Table 4.12 UK Biosimilars: Submarket Forecast, 2011-2022
Table 4.13 Spanish Approved Biosimilars, 2012
Table 4.14 Spanish Biosimilars: Submarket Forecast, 2011-2022
Table 4.15 Italian Biosimilars: Submarket Forecast, 2011-2022
Table 4.16 Japanese Biosimilars: Submarket Forecast, 2011-2022
Table 4.17 Chinese Biosimilars: Submarket Forecast, 2011-2022
Table 4.18 Indian Biosimilars: Submarket Forecast, 2011-2022
Table 4.19 South Korean Biosimilars: Submarket Forecast, 2011-2022
Table 5.1 Monoclonal Antibodies and Fusion Proteins Submarket: Drug Revenues, 2011
Table 5.2 Monoclonal Antibodies: Selected Pipeline Candidates, 2012
Table 5.3 Monoclonal Antibodies and Fusion Proteins Submarket: Revenue Forecast, 2011-2022
Table 5.4 Ten Most Common Cancers by Mortality, 2008 & 2015
Table 5.5 Reditux: Revenue, FY 2008-2011
Table 5.6 Biosimilar Monoclonal Antibodies and Fusion Proteins Submarket: Revenue Forecast, 2011-2022
Table 5.7 Monoclonal Antibodies and Fusion Proteins: Patent Expiries and Peak Revenues, 2012-2019
Table 5.8 Monoclonal Antibodies and Fusion Proteins: Pipeline, 2012
Table 6.1 Insulin Submarket: Drug Revenues, 2011
Table 6.2 Insulin: Selected Pipeline Candidates, 2012
Table 6.3 Insulin Submarket: Revenue Forecast, 2011-2022
Table 6.4 Insulin: Patent Expiries and Peak Revenues, 2014-2019
Table 6.5 Diabetes: Rising Prevalence, 2000 & 2030
Table 6.6 Ageing Global Population, 2009 & 2025
Table 6.7 Biosimilar Insulin Submarket: Revenue Forecast, 2011-2022
Table 7.1 Interferons Submarket: Drug Revenues, 2011
Table 7.2 Pegasys: Revenue, 2009-2011
Table 7.3 Interferons Submarket: Revenue Forecast, 2011-2022
Table 7.4 Oral MS Agents Approved and in Development, 2012
Table 7.5 Biosimilar Interferons Submarket: Revenue Forecast, 2011-2022
Table 7.6 Interferons: Selected Pipeline Candidates, 2012
Table 7.7 Interferons: Patent Expiries and Peak Revenues, 2008-2017
Table 8.1 Erythropoietins Submarket: Drug Revenues, 2011
Table 8.2 Erythropoietins Submarket: Revenue Forecast, 2011-2022
Table 8.3 Erythropoietins: Patent Expiries
Table 8.4 Biosimilar Erythropoietins Submarket: Revenue Forecast, 2011-2022
Table 8.5 G-CSF Submarket: Drug Revenues, 2011
Table 8.6 G-CSF Submarket: Revenue Forecast, 2011-2022
Table 8.7 Biosimilar G-CSF Submarket: Revenue Forecast, 2011-2022
Table 8.8 Growth Hormones Submarket: Drug Revenues, 2011
Table 8.9 Growth Hormones Submarket: Revenue Forecast, 2011-2022
Table 8.10 Biosimilar Growth Hormones Submarket: Revenue Forecast, 2011-2022
Table 9.1 EMA Biosimilar Guidelines, 2005-2011
Table 9.2 EU Biosimilar Approval Application Rejections, 2006-2009
Table 9.3 National Biosimilar Guidelines Drafted, 2005-2012
Table 10.1 World Biosimilars Market: Strengths and Weaknesses, 2012
Table 10.2 World Biosimilars Market: STEP Analysis, 2012-2022
Table 10.3 Major Licensing Deals in Biosimilars, 2010-2011
Table 11.1 Leading Biosimilar Manufacturers, 2012
Table 11.2 3SBio: Revenue, 2006-2010
Table 11.3 3SBio: Revenue by Product, 2008-2010
Table 11.4 3SBio: Biosimilar Pipeline, 2012
Table 11.5 Biocon: Revenue, FY 2009-2011
Table 11.6 SciGen: Biosimilar Portfolio, 2012
Table 11.7 Dr Reddy's Laboratories: Biosimilar Portfolio, 2012
Table 11.8 Intas Biopharmaceuticals: Biosimilar Portfolio, 2012
Table 11.9 Reliance Life Sciences: Biosimilar Portfolio, 2012
Table 11.10 Sandoz: Biosimilars Revenue, 2009-2011
Table 11.11 Teva: Biosimilars Revenue, 2008-2010
Table 11.12 Wockhardt: Biosimilar Portfolio, 2012
Table 11.13 Zydus Cadila: Approved and Pipeline Biosimilars, 2012
Table 11.14 Merck & Co.: Selected Biosimilars in Development, 2012
List of Figures
Figure 2.1 Comparative Biological Molecule Sizes
Figure 2.2 Key Developments for Biological Drugs, 1922-2002
Figure 3.1 Biological Drugs: Market Shares by Sector, 2011
Figure 3.2 Biological Drugs Market: Drivers and Restraints, 2012-2022
Figure 3.3 Biological Drugs Market: Overall Market Forecast, 2011-2022
Figure 3.4 Biosimilars Market Shares by Sector, 2011
Figure 3.5 Biosimilars Market: Overall Market Forecast, 2011-2022
Figure 3.6 Biosimilars Market: Drivers and Restraints, 2012-2022
Figure 3.7 Biosimilars: Market Shares by Sector, 2016
Figure 3.8 Biosimilars: Market Shares by Sector, 2022
Figure 4.1 Biosimilars: Market Shares by Region, 2011
Figure 4.2 Biosimilars: Market Shares by Region, 2016
Figure 4.3 Biosimilars: Market Shares by Region, 2022
Figure 4.4 Global Pharmaceutical and Generics Markets: US Share, 2011
Figure 4.5 US Biosimilars Submarket: Drivers and Restraints, 2012-2022
Figure 4.6 US Biosimilars: Submarket Forecast, 2011-2022
Figure 4.7 European Biosimilars: Market Shares by Leading Country, 2011
Figure 4.8 European Biosimilars Submarket: Drivers and Restraints, 2012-2022
Figure 4.9 European Biosimilars: Submarket Forecast for Leading Countries, 2011-2022
Figure 4.10 German Biosimilars: Submarket Forecast, 2011-2022
Figure 4.11 French Biosimilars: Market Shares by Sector, 2011
Figure 4.12 French Biosimilars: Submarket Forecast, 2011-2022
Figure 4.13 UK Biosimilars: Submarket Forecast, 2011-2022
Figure 4.14 Spanish Biosimilars: Submarket Forecast, 2011-2022
Figure 4.15 Italian Biosimilars: Submarket Forecast, 2011-2022
Figure 4.16 Japanese Biosimilars Submarket: Drivers and Restraints, 2012-2022
Figure 4.17 Japanese Biosimilars: Submarket Forecast, 2011-2022
Figure 4.18 Chinese Biosimilars Submarket: Drivers and Restraints, 2012-2022
Figure 4.19 Chinese Biosimilars: Submarket Forecast, 2011-2022
Figure 4.20 Indian Biosimilars Submarket: Drivers and Restraints, 2012-2022
Figure 4.21 Indian Biosimilars: Submarket Forecast, 2011-2022
Figure 4.22 South Korean Biosimilars Submarket: Drivers and Restraints, 2012-2022
Figure 4.23 South Korean Biosimilars: Submarket Forecast, 2011-2022
Figure 5.1 Monoclonal Antibodies and Fusion Proteins Submarket: Drug Revenues, 2011
Figure 5.2 Monoclonal Antibodies and Fusion Proteins Submarket: Revenue Forecast, 2011-2022
Figure 5.3 Ten Most Common Cancers by Mortality, 2008 & 2015
Figure 5.4 Reditux: Revenue, FY 2008-2011
Figure 5.5 Biosimilar Monoclonal Antibodies and Fusion Proteins Submarket: Revenue Forecast, 2011-2022
Figure 5.6 Biosimilar Monoclonal Antibodies and Fusion Proteins Submarket: Drivers and Restraints, 2012-2022
Figure 6.1 Insulin Submarket: Drug Revenues, 2011
Figure 6.2 Insulin Submarket: Revenue Forecast, 2011-2022
Figure 6.3 Diabetes: Rising Prevalence, 2000 & 2030
Figure 6.4 Ageing Global Population, 2009 & 2025
Figure 6.5 Biosimilar Insulin Submarket: Revenue Forecast, 2011-2022
Figure 6.6 Biosimilar Insulin Submarket: Drivers and Restraints, 2012-2022
Figure 7.1 Interferons Submarket: Drug Revenues, 2011
Figure 7.2 Pegasys: Revenue, 2009-2011
Figure 7.3 Interferons Submarket: Revenue Forecast, 2011-2022
Figure 7.4 Biosimilar Interferons Submarket: Revenue Forecast, 2011-2022
Figure 7.5 Biosimilar Interferons Submarket: Drivers and Restraints, 2012-2022
Figure 8.1 Erythropoietins Submarket: Drug Revenues, 2011
Figure 8.2 Erythropoietins Submarket: Revenue Forecast, 2011-2022
Figure 8.3 Biosimilar Erythropoietins Submarket: Drivers and Restraints, 2012-2022
Figure 8.4 Biosimilar Erythropoietins Submarket: Revenue Forecast, 2011-2022
Figure 8.5 G-CSF Submarket: Drug Revenues, 2011
Figure 8.6 G-CSF Submarket: Revenue Forecast, 2011-2022
Figure 8.7 Biosimilar G-CSF Submarket: Drivers and Restraints, 2012-2022
Figure 8.8 Biosimilar G-CSF Submarket: Revenue Forecast, 2011-2022
Figure 8.9 Growth Hormones Submarket: Drug Revenues, 2011
Figure 8.10 Growth Hormones Submarket: Revenue Forecast, 2011-2022
Figure 8.11 Biosimilar Growth Hormones Submarket: Revenue Forecast, 2011-2022
Figure 8.12 Biosimilar Growth Hormones Submarket: Drivers and Restraints, 2012-2022
Figure 11.1 3SBio: Revenue, 2006-2010
Figure 11.2 3SBio: Revenue by Product, 2008-2010
Figure 11.3 Biocon: Revenue, FY 2009-2011
Figure 11.4 Sandoz: Biosimilars Revenue, 2009-2011
Figure 11.5 Teva: Biosimilars Revenue, 2008-2010